Female Breast Cancer
28
8
9
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
2 terminated out of 28 trials
50.0%
-36.5% vs benchmark
14%
4 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (28)
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
Melatonin Supplementation and Exercise Program in Breast Cancer Women
Exercise Program on Pain, Physical Function, and Quality of Life in Breast Cancer Survivors
PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Pulsed Electromagnetic Fields for Analgesia Post Mastectomy
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery
Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients
Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
Acupuncture for Joint Symptoms in Patients With Breast Cancer
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
Tomosymthesis for Breast Mass Lesion Characterization
Yoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy